PL1951729T3 - Pochodne pirymidyny połączone przez atom tlenu - Google Patents

Pochodne pirymidyny połączone przez atom tlenu

Info

Publication number: PL1951729T3
Authority: PL; Poland
Prior art keywords: compounds; oxygen linked; pyrimidine derivatives; linked pyrimidine; useful
Prior art date: 2005-11-16

Application number

PL06813132T

Other languages

English (en)

Inventor

Stéphanie Blanchard

Cheng Hsia Angeline Lee

Harish Kumar Mysore Nagaraj

Anders Poulsen

Eric T Sun

Yee Ling Evelyn Tan

Anthony Deodaunia William

Original Assignee

Cti Biopharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-16

Filing date

2006-11-15

Publication date

2015-02-27

2006-11-15 Application filed by Cti Biopharma Corp filed Critical Cti Biopharma Corp

2015-02-27 Publication of PL1951729T3 publication Critical patent/PL1951729T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

PL06813132T 2005-11-16 2006-11-15 Pochodne pirymidyny połączone przez atom tlenu PL1951729T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US73683805P	2005-11-16	2005-11-16
US81733906P	2006-06-30	2006-06-30
US85128306P	2006-10-13	2006-10-13
EP06813132.5A EP1951729B1 (en)	2005-11-16	2006-11-15	Oxygen linked pyrimidine derivatives
PCT/SG2006/000352 WO2007058627A1 (en)	2005-11-16	2006-11-15	Oxygen linked pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
PL1951729T3 true PL1951729T3 (pl)	2015-02-27

Family

ID=38048928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06813132T PL1951729T3 (pl)	2005-11-16	2006-11-15	Pochodne pirymidyny połączone przez atom tlenu

Country Status (20)

Country	Link
US (5)	US8153632B2 (pl)
EP (1)	EP1951729B1 (pl)
JP (2)	JP5380073B2 (pl)
KR (5)	KR101568801B1 (pl)
CN (2)	CN101365703B (pl)
AT (1)	ATE469158T1 (pl)
AU (2)	AU2006316072B2 (pl)
BR (1)	BRPI0618552B8 (pl)
CA (2)	CA2629443C (pl)
CY (1)	CY1116156T1 (pl)
DE (1)	DE602006014579D1 (pl)
DK (2)	DK1951730T3 (pl)
ES (2)	ES2506040T3 (pl)
MY (1)	MY148072A (pl)
NZ (1)	NZ568325A (pl)
PH (1)	PH12012501003B1 (pl)
PL (1)	PL1951729T3 (pl)
PT (2)	PT1951730E (pl)
TW (3)	TWI506029B (pl)
WO (2)	WO2007058627A1 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2549869C (en) *	2003-12-18	2015-05-05	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
JO3088B1 (ar) *	2004-12-08	2017-03-15	Janssen Pharmaceutica Nv	مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es)	2004-12-08	2019-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina inhibidores de cinasas dirigidos a multip
MY167260A (en)	2005-11-01	2018-08-14	Targegen Inc	Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en)	2005-11-16	2019-12-31	Cti Biopharma Corp.	Oxygen linked pyrimidine derivatives
AR061185A1 (es)	2006-05-26	2008-08-13	Chugai Pharmaceutical Co Ltd	Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
MX2009000456A (es)	2006-07-13	2009-01-27	Janssen Pharmaceutica Nv	Derivados de quinazolina mtki.
CN101675059A (zh)	2007-03-01	2010-03-17	中外制药株式会社	大环状化合物
WO2008140419A2 (en) *	2007-05-15	2008-11-20	S*Bio Pte Ltd	Pyridyl substituted pyrimidine derivatives
WO2008140420A2 (en) *	2007-05-15	2008-11-20	S*Bio Pte Ltd	Pyrimidine derivatives
EP2170062A4 (en) *	2007-07-12	2010-12-29	Tragara Pharmaceuticals Inc	METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2009016132A1 (en)	2007-07-27	2009-02-05	Janssen Pharmaceutica Nv	Pyrrolopyrimidines
ES2424982T3 (es)	2008-03-10	2013-10-10	Janssen Pharmaceutica, N.V.	4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK
US8871753B2 (en)	2008-04-24	2014-10-28	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
MX2011006206A (es)	2008-12-11	2011-07-20	S Bio Pte Ltd	Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
EP2376500B1 (en)	2008-12-11	2015-02-25	Cti Biopharma Corp.	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
EP2454266B1 (en) *	2009-07-15	2013-07-10	Cell Therapeutics, Inc.	9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
US9120815B2 (en) *	2010-02-05	2015-09-01	Tragara Pharmaceuticals, Inc.	Solid state forms of macrocyclic kinase inhibitors
TW201206946A (en) *	2010-07-15	2012-02-16	Bristol Myers Squibb Co	Compounds for the reduction of beta-amyloid production
WO2012060847A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
CN102127087B (zh) *	2011-01-21	2012-07-04	江苏先声药物研究有限公司	喹唑啉衍生物
CN102757448B (zh) *	2011-04-26	2016-04-06	中南大学	大环类激酶抑制剂化合物、制备方法及其作为药物的应用
EP2760453B1 (en) *	2011-09-30	2016-05-25	Ipsen Pharma S.A.S.	Macrocyclic lrrk2 kinase inhibitors
US9498471B2 (en)	2011-10-20	2016-11-22	The Regents Of The University Of California	Use of CDK9 inhibitors to reduce cartilage degradation
CN102617599B (zh) *	2012-04-10	2014-04-16	江苏先声药物研究有限公司	大环类化合物及其应用
CA2904148A1 (en) *	2013-03-14	2014-10-02	Concert Pharmaceuticals, Inc.	Deuterated pacritinib
WO2014180524A1 (en) *	2013-05-06	2014-11-13	Merck Patent Gmbh	Macrocycles as kinase inhibitors
MA39822A (fr) *	2014-04-03	2018-02-06	Janssen Pharmaceutica Nv	Dérivés de pyrimidine bicycle
MA39823A (fr) *	2014-04-03	2018-01-09	Janssen Pharmaceutica Nv	Dérivés de pyridine macrocyclique
SI3179992T1 (sl)	2014-08-11	2022-09-30	Acerta Pharma B.V.	Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
TW201618773A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
TW201618772A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
FR3025199B1 (fr) *	2014-09-02	2016-09-23	Pf Medicament	Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
FR3025200B1 (fr)	2014-09-02	2016-09-23	Pf Medicament	Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
TR201904514T4 (tr)	2014-09-17	2019-04-22	Oncodesign Sa	Makrosiklik LRRK2 kinaz inhibitörleri.
CA3000633C (en)	2014-10-14	2023-10-03	The Regents Of The University Of California	Use of cdk9 and brd4 inhibitors to inhibit inflammation
WO2016149031A1 (en) *	2015-03-18	2016-09-22	Newave Pharmaceutical Llc	Covalent inhibitors of cdk-7
CN105061467B (zh) *	2015-08-28	2017-08-25	苏州立新制药有限公司	一种帕克替尼的制备方法
CN105017282B (zh) *	2015-08-28	2017-11-07	苏州明锐医药科技有限公司	帕克替尼的制备方法
EP3355891B1 (en) *	2015-09-28	2021-01-13	CTI Biopharma Corp.	Pacritinib for use in treating transplant rejection
JP6888000B2 (ja) *	2015-10-08	2021-06-16	バイエルファーマアクチエンゲゼルシャフト	新規な修飾された大環状化合物
SG11201808306PA (en) *	2016-03-24	2018-10-30	Tragara Pharmaceuticals Inc	Treatment of cancer with tg02
WO2017196261A1 (en) *	2016-05-11	2017-11-16	National University Of Singapore	Jak and hdac dual-inhibitor compounds
KR102758037B1 (ko) *	2017-08-18	2025-01-22	코테라 바이오사이언스 인코포레이티드	Tg02의 다형성 형태
WO2019079357A1 (en) *	2017-10-17	2019-04-25	Silverback Therapeutics, Inc.	Tnik modulators, conjugates, and uses thereof
CN108864145B (zh) *	2018-09-14	2021-03-30	兆科（广州）肿瘤药物有限公司	一种氧联嘧啶衍生物的纯化方法
US20220008448A1 (en) *	2018-10-01	2022-01-13	Cti Biopharma Corp.	Methods of treating flt3-mutated hematologic cancers
WO2020097396A1 (en) *	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN111269245B (zh) *	2018-12-04	2021-08-27	杭州百新生物医药科技有限公司	一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
WO2020125513A1 (zh) *	2018-12-19	2020-06-25	凯复制药有限公司	作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
WO2020219606A1 (en)	2019-04-22	2020-10-29	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of erk5 inhibitors for treating gliomas in pediatric subjects
WO2021091535A1 (en)	2019-11-05	2021-05-14	Constellation Pharmaceuticals, Inc.	Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020256739A1 (en)	2019-06-21	2020-12-24	Constellation Pharmaceuticals, Inc.	Methods of treating myeloproliferative disorders
WO2020257644A1 (en)	2019-06-21	2020-12-24	Constellation Pharmaceuticals, Inc.	Methods of treating myeloproliferative disorders
CN112321604A (zh) *	2019-08-05	2021-02-05	华东理工大学	大环类jak2抑制剂及其应用
JP7671284B2 (ja)	2019-10-04	2025-05-01	ティーエーイーライフサイエンシーズ	Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
CN113583020B (zh) *	2020-04-30	2022-04-22	百极弘烨（广东）医药科技有限公司	一种jak2抑制剂及应用
CN113735879B (zh) *	2020-05-27	2022-05-17	百极弘烨（广东）医药科技有限公司	一种大环jak抑制剂及其应用
WO2022056092A1 (en) *	2020-09-11	2022-03-17	Cti Biopharma Corp.	Methods of treating viral infection
CN115490705B (zh) *	2021-06-18	2025-04-01	成都凡诺西生物医药科技有限公司	N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) *	2021-07-27	2023-08-11	中国药科大学	一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) *	2022-01-28	2023-07-25	山东大学	一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) *	2022-10-24	2024-05-03	科辉智药生物科技(深圳)有限公司	作为cdk9抑制剂的大环类化合物及其应用
CN117447407B (zh) *	2023-12-19	2024-06-11	潍坊医学院	一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5811515A (en)	1995-06-12	1998-09-22	California Institute Of Technology	Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
MX210210B (es)	1997-06-27	2002-09-06	Ciba Sc Holding Ag	Nuevos catalizadores
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en)	2001-08-31	2002-08-13	The Research Foundation Of State University Of New York	Method for reducing hypertrophy and ischemia
DE10239042A1 (de) *	2002-08-21	2004-03-04	Schering Ag	Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7388010B2 (en) *	2002-10-29	2008-06-17	Banyu Pharmaceutical Co., Ltd.	Quinoxalinone derivatives
US7151096B2 (en) *	2003-03-05	2006-12-19	Irm Llc	Cyclic compounds and compositions as protein kinase inhibitors
US7163939B2 (en) *	2003-11-05	2007-01-16	Abbott Laboratories	Macrocyclic kinase inhibitors
US20050096324A1 (en) *	2003-11-05	2005-05-05	Zhi-Fu Tao	Macrocyclic kinase inhibitors
CA2549728C (en) *	2003-12-18	2015-07-21	Janssen Pharmaceutica N.V.	3-cyano-quinoline derivatives with antiproliferative activity
CA2549869C (en) *	2003-12-18	2015-05-05	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
MY169441A (en) *	2004-12-08	2019-04-11	Janssen Pharmaceutica Nv	2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) *	2012-11-16	2015-06-02	Robert Bosch Gmbh	Collision mitigation systems and methods using driver attentiveness

2006
- 2006-11-15 CN CN2006800506549A patent/CN101365703B/zh active Active
- 2006-11-15 DK DK06813133.3T patent/DK1951730T3/da active
- 2006-11-15 KR KR1020147003871A patent/KR101568801B1/ko active Active
- 2006-11-15 AU AU2006316072A patent/AU2006316072B2/en active Active
- 2006-11-15 PH PH1/2012/501003A patent/PH12012501003B1/en unknown
- 2006-11-15 TW TW095142296A patent/TWI506029B/zh active
- 2006-11-15 TW TW103101503A patent/TWI525096B/zh active
- 2006-11-15 DK DK06813132.5T patent/DK1951729T3/da active
- 2006-11-15 CA CA2629443A patent/CA2629443C/en active Active
- 2006-11-15 TW TW95142288A patent/TWI407961B/zh active
- 2006-11-15 KR KR1020087013543A patent/KR101499594B1/ko active Active
- 2006-11-15 CA CA2629455A patent/CA2629455C/en active Active
- 2006-11-15 AU AU2006316071A patent/AU2006316071B2/en active Active
- 2006-11-15 CN CN2006800506765A patent/CN101360751B/zh active Active
- 2006-11-15 ES ES06813132.5T patent/ES2506040T3/es active Active
- 2006-11-15 US US12/093,867 patent/US8153632B2/en active Active
- 2006-11-15 KR KR1020147003872A patent/KR101513492B1/ko active Active
- 2006-11-15 KR KR20087013542A patent/KR20080090390A/ko not_active Ceased
- 2006-11-15 PT PT06813133T patent/PT1951730E/pt unknown
- 2006-11-15 AT AT06813133T patent/ATE469158T1/de active
- 2006-11-15 PT PT68131325T patent/PT1951729E/pt unknown
- 2006-11-15 NZ NZ568325A patent/NZ568325A/en unknown
- 2006-11-15 PL PL06813132T patent/PL1951729T3/pl unknown
- 2006-11-15 ES ES06813133T patent/ES2346791T3/es active Active
- 2006-11-15 JP JP2008541129A patent/JP5380073B2/ja active Active
- 2006-11-15 DE DE602006014579T patent/DE602006014579D1/de active Active
- 2006-11-15 MY MYPI20081674 patent/MY148072A/en unknown
- 2006-11-15 JP JP2008541128A patent/JP5225856B2/ja active Active
- 2006-11-15 EP EP06813132.5A patent/EP1951729B1/en active Active
- 2006-11-15 KR KR1020147024470A patent/KR101576159B1/ko active Active
- 2006-11-15 US US12/093,874 patent/US8143255B2/en active Active
- 2006-11-15 WO PCT/SG2006/000352 patent/WO2007058627A1/en not_active Ceased
- 2006-11-15 WO PCT/SG2006/000353 patent/WO2007058628A1/en not_active Ceased
- 2006-11-15 BR BRPI0618552A patent/BRPI0618552B8/pt active IP Right Grant
2012
- 2012-02-13 US US13/371,837 patent/US9133214B2/en active Active
- 2012-04-04 US US13/438,989 patent/US8415338B2/en active Active
2013
- 2013-02-20 US US13/771,546 patent/US9573964B2/en active Active
2014
- 2014-09-25 CY CY20141100782T patent/CY1116156T1/el unknown

Also Published As

Publication number	Publication date
KR20140037256A (ko)	2014-03-26
BRPI0618552A2 (pt)	2011-09-06
ES2506040T3 (es)	2014-10-13
US8153632B2 (en)	2012-04-10
TWI407961B (zh)	2013-09-11
CN101360751B (zh)	2011-09-14
CN101360751A (zh)	2009-02-04
US20090075999A1 (en)	2009-03-19
KR101568801B1 (ko)	2015-11-12
US8143255B2 (en)	2012-03-27
US20130172338A1 (en)	2013-07-04
CY1116156T1 (el)	2017-02-08
AU2006316072A1 (en)	2007-05-24
EP1951729A1 (en)	2008-08-06
EP1951729A4 (en)	2009-09-23
JP2009515954A (ja)	2009-04-16
CA2629455A1 (en)	2007-05-24
AU2006316071B2 (en)	2011-02-17
TW200738735A (en)	2007-10-16
PH12012501003A1 (en)	2012-10-29
US20120142680A1 (en)	2012-06-07
MY148072A (en)	2013-02-28
CN101365703B (zh)	2013-11-06
JP5380073B2 (ja)	2014-01-08
TW201418263A (zh)	2014-05-16
US8415338B2 (en)	2013-04-09
US9573964B2 (en)	2017-02-21
KR101576159B1 (ko)	2015-12-09
ES2346791T3 (es)	2010-10-20
DK1951729T3 (da)	2014-10-06
TWI506029B (zh)	2015-11-01
AU2006316072B2 (en)	2011-12-22
PT1951730E (pt)	2010-08-27
DK1951730T3 (da)	2010-09-27
ATE469158T1 (de)	2010-06-15
CA2629443C (en)	2016-12-13
KR20080090390A (ko)	2008-10-08
KR20140117679A (ko)	2014-10-07
DE602006014579D1 (de)	2010-07-08
BRPI0618552B1 (pt)	2021-04-06
BRPI0618552B8 (pt)	2021-05-25
US20120196855A1 (en)	2012-08-02
CA2629443A1 (en)	2007-05-24
HK1124040A1 (en)	2009-07-03
JP5225856B2 (ja)	2013-07-03
US9133214B2 (en)	2015-09-15
WO2007058627A1 (en)	2007-05-24
PH12012501003B1 (en)	2018-04-06
US20090258886A1 (en)	2009-10-15
TWI525096B (zh)	2016-03-11
WO2007058628A1 (en)	2007-05-24
KR101513492B1 (ko)	2015-04-20
AU2006316071A1 (en)	2007-05-24
KR20080086443A (ko)	2008-09-25
TW200736262A (en)	2007-10-01
HK1123282A1 (en)	2009-06-12
KR101499594B1 (ko)	2015-03-09
CA2629455C (en)	2017-01-03
CN101365703A (zh)	2009-02-11
PT1951729E (pt)	2014-10-02
KR20140037257A (ko)	2014-03-26
NZ568325A (en)	2011-05-27
JP2009517344A (ja)	2009-04-30
EP1951729B1 (en)	2014-06-25

Publication	Publication Date	Title
PL1951729T3 (pl)	2015-02-27	Pochodne pirymidyny połączone przez atom tlenu
MY150993A (en)	2014-03-31	Pyrimidine substituted purine derivatives
MX2011006959A (es)	2011-12-06	Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
MX2009010047A (es)	2009-12-04	Compuestos quimicos.
MX2009010045A (es)	2009-12-04	Compuestos quimicos.
MX2007009649A (es)	2007-11-15	Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2010111406A3 (en)	2011-07-07	Purine derivatives useful as anti - cancer agents
MY191349A (en)	2022-06-17	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
IL184872A0 (en)	2007-12-03	Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en)	2007-12-03	Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
MX2009009537A (es)	2009-09-16	Nanoparticula que comprende rapamicina y albumina como agente anticancer.
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TNSN07322A1 (en)	2008-12-31	Pyrimidine derivatives for treatment of hyperproliferative disorders
MY179527A (en)	2020-11-10	Catecholamine derivatives useful for the treatment of parkinson's disease
TNSN08370A1 (en)	2009-12-29	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010013682A (es)	2011-03-15	Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2010003269A (es)	2010-08-02	Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
TW200738659A (en)	2007-10-16	Novel compounds
MX2007007027A (es)	2007-07-04	Derivados piperazinilpiridina como agentes anti-obesidad.
EP1812112A4 (en)	2009-11-04	CHEMICAL COMPOUNDS
WO2008140420A3 (en)	2009-04-30	Pyrimidine derivatives
EP2124554A4 (en)	2009-12-30	COMPOSITIONS AND METHODS FOR CANCER TREATMENT
TW200745102A (en)	2007-12-16	Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
TW200640904A (en)	2006-12-01	Quinazoline derivatives
TW200738611A (en)	2007-10-16	9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments